Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2007

View Archived Issues

Trial finds hMaxi-K gene transfer safe in erectile dysfunction patients

Major bear bile component may be useful to prevent retinal degeneration

MVA-BN-HER-2 breast cancer vaccine cleared for clinical trials

Cytokinetics and Amgen form strategic alliance in heart failure

Ozarelix cleared for phase IIb study in BPH

Development plans updated for CPP-109 in drug addiction

Antigen challenge study of Aerovant in asthma meets endpoints

IMC-3G3 begins phase I study in solid tumors

Warner Chilcott and Foamix to develop antibiotic foam for acne

Sigma-Aldrich grants Pfizer research license to utilize ddRNAi technology

Reolysin to be studied with gemcitabine in advanced cancers

bioMerieux and ExonHit target prostate cancer in new screening program

Roche and Synosis to explore drugs' potential for CNS disorders

QLT receives final payment for generic derma and manufacturing business

Genaera ends Evizon program and restructures

ARC-1779 begins phase I program

Medivir files to begin phase I trials of cathepsin K inhibitor MIV-701

Rotigotine patch effective for early-stage Parkinson's disease

Merck KGaA patents novel tyrosinase inhibitors

Novel antiinflammatory agents described in recent patents

Recent patents report discovery of novel oncolytic drugs

Alimta approved for malignant pleural mesothelioma in Japan

Pivotal study of ipilimumab in metastatic melanoma completes enrollment

Pivotal study under way for Allovectin-7 in metastatic melanoma

Enrollment begins in phase II trial of rNAPc2 in metastatic colorectal carcinoma

Biogen Idec to acquire Syntonix

New phase II study investigates 6R-BH4 in symptomatic peripheral arterial disease

Testosterone gel for Alzheimer's disease / News in Context